TY  - BOOK
AU  - Rana Salah Moawad Abdelhady
AU  - Ahmed Hosni Kama , 
AU  - Hend Ibrahim Hassan Shousha  , 
AU  - Iman Mohammed Hamza , 
TI  - Hepatic arterial chemoperfusion in treatment of advanced hepatocellular carcinoma with portal vein thrombosis / 
PY  - 2019///
CY  - Cairo : 
PB  - Rana Salah Moawad Abdelhady , 
KW  - Hepatic arterial infusion chemotherapy (HAIC)
KW  - Hepatocellular carcinoma (HCC)
KW  - Sorafenib
N1  - Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine; Issued also as CD
N2  - orafenib, the multi-kinase inhibitor, is the standard of care for patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) according to EASL guidelines. Other guidelines as the Japanese and Korean recommended hepatic arterial infusion chemotherapy (HAIC) as first line for patients with PVTT followed by Sorafenib as second line and keeping Sorafenib as first line for advanced HCC without PVTT. Aim of work:  The aim of this study is to describe the treatment efficacy and survival benefits of HAIC for patients with advanced HCC and PVTT, BCLC-C with compensated cirrhosis (Child-Pugh A) in comparison with Sorafenib as standard of care therapy for such patients versus Best Supportive Care (BSC).  Patients and methods:  This study  included  ninety one  patients  with  advanced  HCC  and PVTT  who  were recruited from multidisciplinary HCC clinic, Kasr-Alainy, in the period fromApril 2016 till June 2017.Patients were divided into three groups: Group 1: 20 treated with HAIC, The patients received arterial infusion of chemotherapeutic agents in the form of 50 mg Adriamycin and 50 mg Cisplatin.Group 2:42 patients were treated with BSC and Group 3: 29 patients were treated with Sorafenib. The dose of sorafenib was adjusted according to adverse events. Patients were followed  up  for  assessment  and  comparison  of  treatment  outcome  by  modified  RECIST criteriaand survival
UR  - http://172.23.153.220/th.pdf
ER  -